Abstract The incidence of esophageal cancer ranks third among all malignant tumors in China. Neoadjuvant chemoradiotherapy followed by radical surgery is the standard treatment for locally advanced esophageal cancer. Whether the tumor lesions can achieve complete pathological remission after neoadjuvant chemoradiotherapy provide profound guidance for subsequent treatment. In this article, research progresses on the application of pathological, radiological and biological approaches to evaluate and predict the tumor response to neoadjuvant chemoradiotherapy were reviewed.
Fund:Shanghai Pujiang Program (18PJD046);Shanghai Chest Hospital Project of Collaborative Innovation (YJXT20190202Z)
Corresponding Authors:
Fu Xiaolong, Email:xlfu1964@126.com
Cite this article:
Li Yue,Yu Wen,Fu Xiaolong. Research progress on prediction methods for esophageal cancer response to neoadjuvant chemoradiotherapy[J]. Chinese Journal of Radiation Oncology, 2021, 30(8): 853-857.
Li Yue,Yu Wen,Fu Xiaolong. Research progress on prediction methods for esophageal cancer response to neoadjuvant chemoradiotherapy[J]. Chinese Journal of Radiation Oncology, 2021, 30(8): 853-857.
[1] Montgomery EA. Oesophageal Cancer[M]//Stewart BW, Wild CP, eds. World cancer report 2014. Geneva:World Health Organization, 2014:528-543. [2] Arnold M, Soerjomataram I, Ferlay J, et al. Global incidence of oesophageal cancer by histological subtype in 2012[J]. Gut, 2015, 64(3):381-387. DOI:10.1136/gutjnl-2014-308124. [3] Polednak AP. Trends in survival for both histologic types of esophageal cancer in U. S. surveillance, epidemiology and end results areas[J]. Int J Cancer, 2003, 105(1):98-100. DOI:10.1002/ijc.11029. [4] Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS):long-term results of a randomised controlled trial[J]. Lancet Oncol, 2015, 16(9):1090-1098. DOI:10.1016/S1470-2045(15)00040-6. [5] Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival[J]. J Clin Oncol, 2005, 23(19):4330-4337. DOI:10.1200/JCO.2005.05.017. [6] Bedenne L, Michel P, Bouché O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus:FFCD 9102[J]. J Clin Oncol, 2007, 25(10):1160-1168. DOI:10.1200/JCO.2005.04.7118. [7] Noordman BJ, Wijnhoven BPL, Lagarde SM, et al. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer:a steppedwedge cluster randomised trial[J]. BMC Cancer, 2018, 18(1):142. DOI:10.1186/s12885-018-4034-1. [8] Bedenne L, Mariette C. Comparison of systematic surgery versus surveillance and rescue surgery in operable oesophageal cancer with a complete clinical response to radiochemotherapy (esostrate)[DB/OL][2019-12-20]. https://clinicaltrials. gov/ct2/show/NCT02551458. [9] Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation[J]. Cancer, 2005, 103(7):1347-1355. DOI:10.1002/cncr.20916. [10] Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO):a prospective multicentre, diagnostic cohort study[J]. Lancet Oncol, 2018, 19(7):965-974. DOI:10.1016/S1470-2045(18)30201-8. [11] Ajani JA, Correa AM, Hofstetter WL, et al. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer[J]. Ann Oncol, 2012, 23(10):2638-2642. DOI:10.1093/annonc/mds210. [12] van Rossum PSN, Goense L, Meziani J, et al. Endoscopic biopsy andEUSfor the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer:a systematic review and meta-analysis[J]. Gastrointest Endosc, 2016, 83(5):866-879. DOI:10.1016/j.gie.2015.11.026. [13] van der Bogt RD, Noordman BJ, Krishnadath KK, et al. Endoscopic ultrasound measurements for detection of residual disease after neoadjuvant chemoradiotherapy for esophageal cancer[J]. Endoscopy, 2019, 51(4):326-332. DOI:10.1055/a-0795-3220. [14] Zhang XY, Yan WP, Sun Y, et al. CT signs can predict treatment response and long-term survival:a study in locally advanced esophageal cancer with preoperative chemotherapy[J]. Ann Surg Oncol, 2015, 22(Suppl 3):S1380-1387. DOI:10.1245/s10434-015-4531-2. [15] Li SH, Rau KM, Lu HI, et al. Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma[J]. Eur J Cardiothorac Surg, 2012, 42(6):958-964. DOI:10.1093/ejcts/ezs136. [16] Djuric-Stefanovic A, Micev M, Stojanovic-Rundic S, et al. Absolute CT perfusion parameter values after the neoadjuvant chemoradiotherapy of the squamous cell esophageal carcinoma correlate with the histopathologic tumor regression grade[J]. Eur J Radiol, 2015, 84(12):2477-2484. DOI:10.1016/j.ejrad.2015.09.025. [17] Tamandl D, Fueger B, Haug A, et al. A diagnostic algorithm that combines quantitative 18F-FDG PET parameters and contrast-enhanced ct improves posttherapeutic locoregional restaging and prognostication of survival in patients with esophageal cancer[J]. Clin Nucl Med, 2019, 44(1):e13-e21. DOI:10.1097/RLU.0000000000002366. [18] Hagen PV, Heijl MV, Henegouwen MI, et al. Prediction of disease-free survival using relative change in FDG-uptake early during neoadjuvant chemoradiotherapy for potentially curable esophageal cancer:a prospective cohort study[J]. Dis Esophagus, 2017, 30(2):1-7. DOI:10.1111/dote.12479. [19] Malik V, Lucey JA, Duffy GJ, et al. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus[J]. J Nucl Med, 2010, 51(12):1863-1869. DOI:10.2967/jnumed.110.079566. [20] van Heijl M, Omloo JM, van Berge Henegouwen MI, et al. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer[J]. Ann Surg, 2011, 253(1):56-63. DOI:10.1097/SLA.0b013e3181f66596. [21] Li Y, Lin Q, Luo Z, et al. Value of sequential 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET-CTT) in prediction of the overall survival of esophageal cancer patients treated with chemoradiotherapy[J]. Int J Clin Exper Med, 2015, 8(7):10947-10955. [22] Elimova E, Wang X, Etchebehere E, et al. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients[J]. Eur J Cancer, 2015, 51(17):2545-2552. DOI:10.1016/j.ejca.2015.07.044. [23] de Gouw DJJM, Klarenbeek BR, Driessen M, et al. Detecting pathological complete response in esophageal cancer after neoadjuvant therapy based on imaging techniques:a diagnostic systematic review and meta-analysis[J]. J Thora Oncol, 2019, 14(7):1156-1171. DOI:10.1016/j.jtho.2019.04.004. [24] van Rossum PSN, Fried DV, Zhang L, et al. The incremental value of subjective and quantitative assessment of 18F-FDG PET for the prediction of pathologic complete response to preoperative chemoradiotherapy in esophageal cancer[J]. J Nucl Med, 2016, 57(5):691-700. DOI:10.2967/jnumed.115.163766. [25] Beukinga RJ, Hulshoff JB, Mul VEM, et al. Prediction of response to neoadjuvant chemotherapy and radiation therapy with baseline and restaging 18F-FDG pet imaging biomarkers in patients with esophageal cancer[J]. Radiology, 2018, 287(3):983-992. DOI:10.1148/radiol.2018172229. [26] van Rossum PSN, van Lier ALHMW, van Vulpen M, et al. Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer[J]. Radiother Oncol, 2015, 115(2):163-170. DOI:10.1016/j.radonc.2015.04.027. [27] Heethuis SE, van Rossum PSN, Lips IM, et al. Dynamic contrast-enhanced MRI for treatment response assessment in patients with oesophageal cancer receiving neoadjuvant chemoradiotherapy[J]. Radiother Oncol, 2016, 120(1):128-135. DOI:10.1016/j.radonc.2016.05.009. [28] Wu X, Gu J, Wu TT, et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer[J]. J Clin Oncol, 2006, 24(23):3789-3798. DOI:10.1200/JCO.2005.03.6640. [29] Metzger R, Warnecke-Eberz U, Alakus H, et al. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus:ERCC1 gene polymorphisms for prediction of response and prognosis[J]. J Gastrointest Surg, 2012, 16(1):26-34;discussion 34. DOI:10.1007/s11605-011-1700-x. [30] Luthra R, Wu TT, Luthra MG, et al. Gene expression profiling of localized esophageal carcinomas:association with pathologic response to preoperative chemoradiation[J]. J Clin Oncol, 2006, 24(2):259-267. DOI:10.1200/JCO.2005.03.3688. [31] Maher SG, Gillham CM, Duggan SP, et al. Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer[J]. Ann Surg, 2009, 250(5):729-737. DOI:10.1097/SLA.0b013e3181bce7e1. [32] Wen J, Yang H, Liu MZ, et al. Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo-chemoradiotherapy[J]. Ann Oncol, 2014, 25(9):1769-1774. DOI:10.1093/annonc/mdu201. [33] Skinner HD, Lee JH, Bhutani MS, et al. A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma:miRNA predicts response to therapy[J]. Cancer, 2014, 120(23):3635-3641. DOI:10.1002/cncr.28911. [34] Wen J, Luo K, Liu H, et al. MiRNA expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neoadjuvant chemoradiotherapy:[J]. Ann Surg, 2016, 263(5):942-948. DOI:10.1097/SLA.0000000000001489. [35] Okumura H, Uchikado Y, Setoyama T, et al. Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy[J]. Surg Today, 2014, 44(3):421-428. DOI:10.1007/s00595-013-0580-y. [36] Sunada F, Itabashi M, Ohkura H, et al. p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy[J]. World J Gastroenterol, 2005, 11(36):5696-5700. DOI:10.3748/wjg.v11.i36.5696. [37] Sarbia M, Ott N, Pühringer-Oppermann F, et al. The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus[J]. Br J Cancer, 2007, 97(10):1404-1408. DOI:10.1038/sj.bjc.6604037. [38] van Olphen SH, Biermann K, Shapiro J, et al. p53 and SOX2 protein expression predicts esophageal adenocarcinoma in response to neoadjuvant chemoradiotherapy[J]. Ann Surg, 2017, 265(2):347-355. DOI:10.1097/SLA.0000000000001625. [39] Maher SG, McDowell DT, Collins BC, et al. Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation[J]. Ann Surg, 2011, 254(5):809-817. DOI:10.1097/SLA.0b013e31823699f2. [40] Borggreve AS, Mook S, Verheij M, et al. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE):a multicenter observational study[J]. BMC Cancer, 2018, 18(1):1006-1016. DOI:10.1186/s12885-018-4892-6.
2021, Vol. 30 
